EUVIMEDEUVIMED entdecken
Crossref

Medicinal plant raw materials in the pharmaceutical market of Kazakhstan: a comparative analysis of registered products in 2020 and 2025.

Aigul Jussupkaliyeva, Sholpan Akhelova

Journal of Biological Research · 06.04.2026 · 1 (1) · 9-15

DOI: 10.70264/jbr.v1.1.2026.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Research, online erschienen am 06.04.2026. Verfasst von Aigul Jussupkaliyeva und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medicinal plant raw materials are the basis of herbal preparations in medical practice, and studying their range on the pharmaceutical market of Kazakhstan allows us to assess development trends, product expansion, and improvement of quality control standards. The aim of the study was to conduct a comparative analysis of the range, morphological groups, and composition of domestic producers of medicinal plant raw materials registered in the State Register of Medicines of the Republic of Kazakhstan in 2020 and 2025, identifying changes in the nomenclature and distribution according to the ATC (Anatomical Therapeutic Chemical) classification. Open data from the register was used, a retrospective analysis of the quantity and distribution of raw materials by morphological groups and ATC categories was carried out, and information about manufacturers was systematized with verification of botanical names in Microsoft Excel. The results showed that the total number of registered raw materials remained stable (26 items), with Zerde-Fito LLP being the main manufacturer. The emergence of new manufacturers – Daulet-Farm LLP and Karaganda Pharmaceutical Plant LLP was accompanied by the registration of previously absent species, including parmelia thalli and salt marsh grass. The ATС categories have expanded to include new therapeutic areas, and the nomenclature of some species has been refined. The market for medicinal plant raw materials in Kazakhstan remains stable in terms of quantity, while at the same time, there is a structural renewal of the product range, the emergence of new manufacturers, and harmonization of the nomenclature, reflecting the development of phytotherapy and the strengthening of the national pharmaceutical sector.

Zitieren

APA

Jussupkaliyeva, A., & Akhelova, S. (2026). Medicinal plant raw materials in the pharmaceutical market of Kazakhstan: a comparative analysis of registered products in 2020 and 2025. Journal of Biological Research, 1(1), 9-15. https://doi.org/10.70264/jbr.v1.1.2026.2

Vancouver

Jussupkaliyeva A, Akhelova S. Medicinal plant raw materials in the pharmaceutical market of Kazakhstan: a comparative analysis of registered products in 2020 and 2025. Journal of Biological Research. 2026;1(1):9-15. doi:10.70264/jbr.v1.1.2026.2

BibTeX
@article{Jussupkaliyeva2026,
  author = {Jussupkaliyeva, Aigul and Akhelova, Sholpan},
  title = {Medicinal plant raw materials in the pharmaceutical market of Kazakhstan: a comparative analysis of registered products in 2020 and 2025},
  journal = {Journal of Biological Research},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {9--15},
  doi = {10.70264/jbr.v1.1.2026.2}
}
Kostenlos starten →